Trade group warns 0%-15% jump in levy will harm patients in US and Europe by reducing access, disrupting supply chains and cutting R&D
European pharmaceutical firms have condemned the US move to put 15% tariffs on medicines imported from the EU, calling the taxes a “blunt instrument” that would harm patients on both sides of the Atlantic.
They were responding to a White House text of the deal that inferred the 15% baseline rate on imports from the EU would also apply to drugs if the agreement is implemented on the US side on Friday as expected.
